Allston, MA · Founded 2022 · Privately Held (backing)
Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration. InGel Therapeutics is based in Allston, MA and was founded in 2022. It was valued at $17 million at its seed round in Jul 2024, the last priced event on record. It has raised $10.8 million across 1 recorded round; the latest was a $350,000 seed round in Jul 2022.
PMV mark · valuation
$17.0M
Oct 2026
Priced at
its seed round
Jul 2024
Total raised
$10.8M
Last round
Seed Round
Jul 2022
Cap table — not yet on record
InGel Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of InGel Therapeutics with a free account
·The complete investor list: 16 names
·Watch InGel Therapeutics: the Monday email on marks, rounds and moves
Where does InGel Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across InGel Therapeutics's 1 recorded funding rounds.
